AFLIBERCEPT

Information current as at: 1 June 2026

PBAC meeting date: March 2024
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Eylea®
Form and strength:
Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:
Bayer Australia Ltd
Condition/indication:
(therapeutic use)
  • Subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration
Listing requested:
Please see PSD for more information
Funding program:
Please see PSD for more information
Request authority level:
Please see PSD for more information
PBAC Submission type:
New PBS listing (Category 2)
Comment:
To be considered at a future PBAC meeting
Other PBAC consideration:
--

Progress Details

Submission received for:
March 2024 PBAC meeting
Opportunity for consumer comment:
Open 22/11/2023 and close 31/01/2024 (see PBS Website)
PBAC meeting:
Held on 13/03/2024
PBAC outcome published:
Not Applicable (see PBAC Outcomes)
Lodgement of required documentation:
Not applicable
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Case ID
a804
Page last updated
31 March 2026
Return to the Medicine Status Listing
v.9.19